Nuvation Bio Inc (NUVB) Stock Price, Quote & News

Company Profile

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; a...

Industry: Biotechnology

Sector: Healthcare

Phone: 332 208 6102

Website: www.nuvationbio.com

Address:

1500 Broadway, Suite 1401, New York, United States

macstock Jan. 17 at 1:02 AM

$NUVB buying more!

0 · Reply

Incognito_21 Jan. 16 at 11:33 PM

$NUVB 5.53 ish is the biggest gap down looking at the 1 month by 1 day chart zoomed out ….this is about to turn upward buy now. 15 by 2nd quarter reporting.

0 · Reply

Bio_Invest101 Jan. 16 at 11:27 PM

$NUVB Put down my money where my mouth is. Will grab more if we ever see 4 and 5. IMO today’s $5 is old $2-3 just 5-6 months ago. OGs who’s gone through the shenanigans during the FDA approval time from June to OCT know how dirty the shorts played the games. As I said b4 nothing shocked me anymore in this market. Find time to read the lastest Cooperation deck during the weekend and stay strong. Also google/AI our new worldwide partner for Ibtrozi and I think they are very good. https://s27.q4cdn.com/855249317/files/doc_presentations/2026/Jan/Nuvation-Bio-Corporate-Presentation-January-2026.pdf

1 · Reply

JanetBSmellin Jan. 16 at 9:11 PM

$NUVB FINY exchange being a real P.O.S. 🤬

0 · Reply

Sooners55 Jan. 16 at 8:43 PM

$NUVB not sure how much more good news we can take. But I’ll be adding in the next week or two.

0 · Reply

Shagg85 Jan. 16 at 8:40 PM

$NUVB RELAX!!!!! There has been absolutely no bad news. This ran from $ 4.50 to almost $10 in a month. It’s pulling back like it should. This is the stock market!!!! If you have bought long then sit back and relax and enjoy the ride to 20 or 30 within the next 2 to 3 years. Unless it gets bought out earlier. But my opinion Dr. Hung won’t sell I believe he’s got some big plans over the next few years. MM’s are creating liquidity for the next big run up.

0 · Reply

AdiDasRom Jan. 16 at 8:31 PM

$NUVB

0 · Reply

zawojak Jan. 16 at 8:30 PM

$NUVB 4$ next week Friday

1 · Reply

jb06000 Jan. 16 at 8:28 PM

$NUVB can’t wait for $NUVL to show liver toxicity

0 · Reply

JFais Jan. 16 at 8:17 PM

Several more price alerts going off today, such as $NUVB in $5S

1 · Reply

Nuvation Bio Inc. (NUVB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 8:00 AM EST - 4 days ago

Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:30 AM EST - 4 days ago

Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan

Jan 6, 2026, 4:05 PM EST - 10 days ago

Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 6, 2025, 10:40 PM EST - 5 weeks ago

Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List

Dec 3, 2025, 11:53 AM EST - 6 weeks ago

Nuvation Bio Inc. (NUVB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 8:00 AM EST - 6 weeks ago

Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology

Nov 29, 2025, 4:37 AM EST - 7 weeks ago

Nuvation Bio: A Strong Company Now Fairly Priced

Nov 26, 2025, 4:05 PM EST - 7 weeks ago

Nuvation Bio to Participate in Upcoming Investor Conferences

Nov 21, 2025, 10:13 PM EST - 2 months ago

Nuvation Bio Inc. (NUVB) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 7, 2025, 5:23 PM EST - 2 months ago

Nuvation Bio: Ibtrozi's Rollout So Far Confirms Bullish Case

Nov 3, 2025, 9:46 PM EST - 2 months ago

Nuvation Bio Inc. (NUVB) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 4:05 PM EST - 2 months ago

Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 23, 2025, 7:30 AM EDT - 3 months ago

Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma

Oct 20, 2025, 4:05 PM EDT - 3 months ago

Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025

Sep 30, 2025, 7:30 AM EDT - 3 months ago

Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer

Sep 29, 2025, 1:15 PM EDT - 3 months ago

3 Of My Favorite Biotech Stocks Under $10

DVAX FOLD MRNA PFE

Sep 19, 2025, 7:30 AM EDT - 4 months ago

Nuvation Bio Receives Approval from Japan's Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

Sep 15, 2025, 12:27 PM EDT - 4 months ago

Nuvation Bio: A Rare Gem In The Risky Biotech Space

Sep 7, 2025, 6:00 AM EDT - 4 months ago

Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer

Sep 5, 2025, 10:39 AM EDT - 4 months ago

Top 2 Health Care Stocks That May Plunge This Month

ESPR

Aug 28, 2025, 12:16 PM EDT - 5 months ago

Nuvation Bio: What To Expect From IBTROZI Launch?

Aug 7, 2025, 7:30 AM EDT - 5 months ago

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 5, 2025, 8:00 AM EDT - 5 months ago

Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

Jul 24, 2025, 4:05 PM EDT - 6 months ago

Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

Jun 24, 2025, 7:00 AM EDT - 7 months ago

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers

Jun 16, 2025, 7:30 AM EDT - 7 months ago

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc.

Jun 11, 2025, 1:45 PM EDT - 7 months ago

US FDA approves Nuvation Bio's lung cancer therapy

Jun 11, 2025, 1:20 PM EDT - 7 months ago

U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer

May 21, 2025, 4:05 PM EDT - 8 months ago

Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting

May 13, 2025, 4:05 PM EDT - 8 months ago

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025

May 11, 2025, 10:05 PM EDT - 8 months ago

Nuvation Bio Inc. (NUVB) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:05 PM EDT - 9 months ago

Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025, 9:07 AM EDT - 9 months ago

Nuvation Bio: A Real Shot To Move The Needle In Lung Cancer Subtypes

May 1, 2025, 4:05 PM EDT - 9 months ago

Nuvation Bio to Present at The Citizens Life Sciences Conference

Apr 22, 2025, 4:05 PM EDT - 9 months ago

Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025

Apr 2, 2025, 8:00 AM EDT - 10 months ago

Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference

Mar 25, 2025, 4:45 PM EDT - 10 months ago

Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025

Mar 25, 2025, 8:00 AM EDT - 10 months ago

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025

Mar 6, 2025, 4:30 PM EST - 11 months ago

Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 3, 2025, 8:35 AM EST - 11 months ago

Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners

Feb 24, 2025, 8:00 AM EST - 11 months ago

Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 1:49 PM EST - 11 months ago

Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm

Feb 13, 2025, 5:09 PM EST - 1 year ago

Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst

Feb 3, 2025, 8:00 AM EST - 1 year ago

Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer

Jan 6, 2025, 4:05 PM EST - 1 year ago

Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 8:00 AM EST - 1 year ago

Nuvation Bio Receives Approval from China's National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

Jan 2, 2025, 7:00 PM EST - 1 year ago

Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration

Dec 23, 2024, 8:00 AM EST - 1 year ago

U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio's New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer

Dec 20, 2024, 7:10 AM EST - 1 year ago

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

macstock Jan. 17 at 1:02 AM

$NUVB buying more!

0 · Reply

Incognito_21 Jan. 16 at 11:33 PM

$NUVB 5.53 ish is the biggest gap down looking at the 1 month by 1 day chart zoomed out ….this is about to turn upward buy now. 15 by 2nd quarter reporting.

0 · Reply

Bio_Invest101 Jan. 16 at 11:27 PM

1 · Reply

JanetBSmellin Jan. 16 at 9:11 PM

$NUVB FINY exchange being a real P.O.S. 🤬

0 · Reply

Sooners55 Jan. 16 at 8:43 PM

$NUVB not sure how much more good news we can take. But I’ll be adding in the next week or two.

0 · Reply

Shagg85 Jan. 16 at 8:40 PM

0 · Reply

AdiDasRom Jan. 16 at 8:31 PM

$NUVB

0 · Reply

zawojak Jan. 16 at 8:30 PM

$NUVB 4$ next week Friday

1 · Reply

jb06000 Jan. 16 at 8:28 PM

$NUVB can’t wait for $NUVL to show liver toxicity

0 · Reply

JFais Jan. 16 at 8:17 PM

Several more price alerts going off today, such as $NUVB in $5S

1 · Reply

JuggernautRaider Jan. 16 at 8:05 PM

$NUVB I would recommend Symphony demand data instead of IQVIA but confirm their capture rate. But the data is very expensive - Symphony usually charges half of what IQVIA does. You should just buy more shares if you believe 🏦 I may ask Symphony for an estimate on Tonmya demand for $TNXP soon and see what they’re capturing… although will likely get it for free from other sources 💪 Also an FYI for $MIST and $KALV who want to track their recent approvals trends here in the USA 🇺🇸

1 · Reply

Gabriel_DS Jan. 16 at 8:00 PM

$NUVB and I thought the next '5' I would see was $15🤨

0 · Reply

ocatraps Jan. 16 at 7:46 PM

$NUVB will the bleeding ever stop?

1 · Reply

Frida_m Jan. 16 at 7:24 PM

$NUVB this stock is no brainier Good price to add [email protected] today Will see reversal soon

0 · Reply

Ahebe42 Jan. 16 at 7:20 PM

$NUVB they finally did it

0 · Reply

sv__ Jan. 16 at 6:21 PM

$NUVB Added. Seems like it's preparing for some huge moves in 2026.👀

0 · Reply

Frida_m Jan. 16 at 6:14 PM

$NUVB started position in MIST this week Not loving there management as much as NUVB Possible BO candidate

1 · Reply

JanetBSmellin Jan. 16 at 5:52 PM

$NUVB added

0 · Reply

jb06000 Jan. 16 at 5:24 PM

$NUVB added

0 · Reply

Frida_m Jan. 16 at 5:21 PM

$NUVB added

0 · Reply

JuggernautRaider Jan. 16 at 4:41 PM

$NUVB ridiculously undervalued. Buying the dip 💎 👊

2 · Reply

HazelNewton Jan. 16 at 4:37 PM

$NUVB A quiet accumulation, any volume surge could ignite a bigger move

1 · Reply

Market Cap	2.10B
Revenue (ttm)	7.87M
Net Income (ttm)	-567.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-7,216.52%
Debt to Equity Ratio	0.16

Volume	5,400,300
Avg Vol	7,789,998
Day's Range	N/A - N/A
Shares Out	342.83M
Stochastic %K	1%
Beta	1.54
Analysts	Strong Sell
Price Target	$11.22